• Autophagy in Paediatric Crohn's Disease

  NCT05842564

  Not yet recruitingInterventionalNot ApplicableUpdated Dec 12, 2024
• Research and Follow-up of the Determinants of the Progression and Complications of Inflammatory Bowel Diseases Treated or Not With Immunosuppressants.

  NCT07172945

  Not yet recruitingInterventionalNot ApplicableUpdated Sep 15, 2025
• Evaluation of Molecular Mechanisms of Non-response to Therapy in Patients With Inflammatory Bowel Disease

  NCT05733845

  RecruitingInterventionalNot ApplicableUpdated May 6, 2025
• Impact Of The Gut Microbiota On Host Cells Energy Metabolism in Health And In Inflammatory Bowel Disease

  NCT07300553

  RecruitingInterventionalPhase 2Updated Mar 12, 2026
• Observational Prospective Study to Identify Intestinal Microbial Profiles in Newly Diagnosed Crohn's Disease Patients

  NCT06324591

  Unknown statusInterventionalNot ApplicableUpdated Mar 22, 2024
• IBD Biomarker Discovery and Validation Platform

  NCT07686406

  RecruitingObservationalUpdated Jul 7, 2026

ClinicalTrials.gov ID

NCT06244849

Lead Sponsor

Hospices Civils de LyonOTHER

Overall Status

Unknown status

Study Type

Interventional

Phase

Not Applicable

Enrollment

170Estimated

Last Update Posted

May 20, 2024Actual

Start Date

Jun 1, 2024Estimated

Primary Completion Date

Jan 1, 2026Estimated

Completion Date

Jan 1, 2026Estimated

Official Title

TOward a Better Understanding of the autoPhagy Machinery for the Identification of Potential Novel Biomarkers and Therapeutic Targets in Crohn's Disease - TOPIC Study

Brief Summary

Crohn's disease (CD) belongs to chronic inflammatory bowel diseases (IBD) affecting over 2 million individuals in the North America and 3.2 million in Europe with an increasing incidence rate in newly industrialized countries experiencing a westernization of lifestyle (1). This highly disabling disease affects patients' life in several ways with severe complications requiring surgery for half of them and is responsible for considerable economic burdens (2,3). Decades of research displayed that CD pathogenesis is determined by inappropriate immune responses towards luminal microbiota in genetically susceptible hosts. Genome-wide association studies (GWAS) have identified autophagy as one of the main pathways associated with susceptibility to CD (4-6). Autophagy is a dynamic process of the lysosomal catabolism, called autophagy flux, which is crucial to degrade and recycle obsolete and deleterious cytosolic components of the cell (7). Autophagy is also the main cell-autonomous process to fight intracellular microorganisms by degrading them, and by contributing to antimicrobial host immune responses. However, the functional consequences of polymorphisms affecting autophagy-associated genes on the dynamic process of autophagy and its real impact on CD pathogenesis remain largely unknown. In addition, CD is associated with a gut microbiota dysbiosis, as exemplified by the higher prevalence of AIEC (a bacterium eliminated by autophagy) in ileal mucosa of CD patients (8-10). Hence, autophagy defect, linked to autophagy SNPs, could contribute to CD-related dysbiosis and to CD activity and severity.

Beyond, CD-associated abnormalities of the autophagy flux may affect the composition of the autophagic cargoes, as well as the one of other vesicular pathway, such as exosomes, known to influence autophagy. These impairments could affect at longer term both cell activities and immune responses, especially in antigen presenting cells, which drive host immune responses.

The TOPIC project concerns translational research, in which we plan to generate a prospective cohort of CD patients giving up the unique opportunity to collect clinical data, to analyse simultaneously the autophagy flux, genetic variants of interest (from blood samples) and intestinal microbiota (from intestinal samples) and allowing to perform more fundamental studies. The results of the fundamental part will allow a better understanding of the pathophysiology of CD, and ultimately better management of these patients.

• Crohn's Disease

• Blood samples
• Stool simple
• Ileocolonic biopsies

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

--- Inclusion Criteria :

For CD patients :

• Aged over 18 years
• Men or non-pregnant women
• Patients with a diagnosis of terminal ileum or ileocolonic CD for at least three months who requires to perform an ileocolonoscopy for routine follow-up
• Inactive and moderately to severely active CD according to the Harvey-Bradshaw index
• Stable doses of oral prednisone (≤30 mg per day) or budesonide (≤9 mg per day), mesalamine, concomitant immunosuppressive agents, biologics including anti-TNF agents, vedolizumab or ustekinumab are allowed at stable dose for at least three months before inclusion.
• Informed written consent
• Beneficiary or beneficiary of a social security system

For non IBD controls :

• Aged over 18 years

• Men or non-pregnant women

• Patients without a diagnosis of Crohn's disease who requires to perform an ileocolonoscopy for routine follow-up

• Informed written consent

• Beneficiary or beneficiary of a social security system

  • Exclusion Criteria * :

For patients and non-IBD controls :

• Existing pregnancy, lactation, or intended pregnancy within the next 15 months
• History of disease, including mental/emotional disorder that might interfere with their participation in the study
• Serious secondary illnesses of an acute or chronic nature, which in the opinion of the investigator renders the patient unsuitable for inclusion into the study
• Inability to comply with the protocol requirements
• Presence of an ileo-/colonic stoma
• Patients with known colonic stricture and exclusive or predominant anal or perineal Crohn's disease lesions
• Known previous or concurrent malignancy (other than that considered surgically cured, with no evidence for recurrence for 5 years)
• Short bowel syndrome
• Concomitant Clostridium difficile superinfection
• Indeterminate colitis
• Concomitant leukocyte apheresis
• Patients who will be exposed to antibiotics 4 weeks prior the inclusion, given the potential impact on the detection of AIEC colonization in ileal biopsies
• Patients who denied the protocol, not ability to accept or sign consent of the protocol
• Subject involved in another interventional research with an exclusion period still in progress at inclusion
• Pregnant women, women in labor or breastfeeding women*.
• Persons deprived of their liberty by a judicial or administrative decision
• Persons under psychiatric care
• Persons admitted to a health or social institution for purposes other than research
• Adults subject to a legal protection measure (guardianship, curatorship)
• Subject involved in another clinical trial

Primary Purpose

Other

Allocation

Non-Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

Hospices Civils de LyonOTHER

Collaborators

Centre International de Recherche en Infectiologie (CIRI)UNKNOWN

Stephane.nancey@chu-lyon.fr04 78 86 12 89 ext. +33